CEO.CA Chairman's Briefing

VANCOUVER, BC--(Marketwired - September 06, 2017) -

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

FinCanna Capital Corp., the royalty investment company for licensed medical cannabis, and Astar Minerals Ltd. (TSX VENTURE: TAR) announce that Morris L. Reid has been appointed to FinCanna's board of directors.

Reid is a highly accomplished and globally recognized corporate and political strategist. He is currently partner in the Washington, D.C. and London offices of Mercury, the leading high-stakes public strategy firm that represents the world's most successful companies, leading advocacy groups, governments, political parties, NGOs, and prominent public and political figures.

Reid has worked extensively with high-profile individuals, government officials and corporate executives, advising on high-level political and corporate issues for more than 15 years. His public affairs advisory work focuses on brand building, international relations and advocacy, crisis and reputation management.

He has designed and executed lucrative business development plans, including business matchmaking and securing foreign direct investment, and has worked in Asia, Latin America, and across the Middle East and Africa in both the public and private sectors. Reid also advises prime ministers, finance ministers, foreign ministers and health ministers in some of the world's most prominent emerging markets.

"Morris represents another outstanding addition to our board of directors," said Andriyko Herchak, president and CEO of FinCanna Capital. "His global vision, broad knowledge and extraordinary talent as a high-level corporate communicator and strategist will be valuable assets to FinCanna as we seek out and develop best-in-class licensed medical cannabis companies. He reflects the high-caliber of corporate governance we've been establishing for FinCanna as the leading investment company in our industry."

Reid's contributions as an expert in political and business marketing has been featured by several major media outlets, including BBC, CNN, CNBC, FOX News, MSNBC, as well as the New York Times, USA Today, Financial Times and Forbes.

"I am excited to join the board of FinCanna at this pivotal stage in its development," said Reid. "The medical cannabis industry is rapidly growing and evolving, and FinCanna represents an excellent way to participate in what is shaping up to be a very significant, multi-billion-dollar global industry."

Reid's board appointment is expected to be ratified at the upcoming FinCanna shareholders meeting.

Other members of the FinCanna's leadership team include:

Andriyko Herchak (CPA, CA), president, CEO and director, has more than 20 years of executive leadership experience with publicly traded companies. He was the previously CFO of Hathor Exploration, a Canadian mineral exploration and development company that raised C$100 million and was sold for C$650 million cash to Rio Tinto. Andriyko was also the former CFO of Playground Real Estate, an international sales and marketing company that generated US$1.4 billion in annual sales before its parent company, Intrawest, was acquired.

Robert Scott (CPA, CA, CFA), chief financial officer, has more than 20 years of experience in corporate finance, including merchant and commercial banking with a major Canadian bank. He has served on the management teams and boards of a number of Canadian publicly traded companies and has listed several companies on the TSX Venture Exchange.

Jeffery Tindale, director, has more than 15 years of experience in merchant banking and corporate advisory services. He brings to the board a strong background in corporate governance, finance, mergers and acquisitions.

Gaynell Rogers, board advisor, is recognized as an expert voice of the medical cannabis industry in the United States and is also a highly respected publicity and media expert and came to the industry as a twice cancer survivor. Gaynell is a senior consultant to Harborside, considered a model and the largest medical cannabis dispensary in the U.S. and has acted as a Sr. publicist for Lucasfilm Ltd. and was Head of Feature Film Publicity for Pixar. She secured the creation of the first cannabis mini series TV show "Weed Wars" on The Discovery Channel in 2010, two Fortune magazine covers and multiple New York Times features and well as many national and international stories for the industry. An active philanthropist for many causes, Gaynell has served on multiple boards throughout her career.

Miguel Motta, board advisor, is the president, CEO and director of Cultivation Technologies Inc. (CTI), FinCanna's flagship investment portfolio company. He previously led global strategy for US$1 billion portfolio of agricultural products as Monsanto executive, a precision agriculture, Fortune 150 company. He is also the former president & CEO of SGB Inc., a venture capital backed company.

Eric Mathur, board advisor, is the chief science officer at CTI and spearheads the Cannabis molecular breeding program aimed at producing purified genetic lines with cannabinoid and terpenoid profiles tailored to specific medical indications. Eric has 40 years of experience in applied biotechnology with knowledge and hands-on expertise in plant molecular breeding, genome sciences, microbiology and nutraceutical research. He has a successful track record of leveraging modern genomic tools and quantitative agronomic methods to improve crop performance. Eric is an influential and respected strategic advisor in global biotechnology, a renowned lecturer and inventor on over 100 patents and has authored more than 50 peer-reviewed publications.

On July 13, 2017, FinCanna and Astar entered into a binding agreement pursuant to which Astar will acquire all of the issued and outstanding common shares of FinCanna on a one for one basis (the "Transaction").

About FinCanna Capital Corp.

FinCanna, is a royalty investment company for licensed medical cannabis, with a focus on California. FinCanna, led by a team of finance and industry experts is building its portfolio of investments in scalable, best-in-class projects. FinCanna's flagship investment is with Cultivation Technologies Inc. ("CTI") to provide funding for its fully-entitled, large-scale indoor medical cannabis facility to be developed in Coachella, Southern California. This Coachella Campus will be a state-of-the-art facility that will include cultivation, extraction, manufacturing, testing and distribution.

For additional information visit www.fincannacapital.com

Neither the TSX Venture Exchange or the CSE in any way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

All information contained in this news release with respect to Astar and FinCanna was supplied by the parties, respectively, for inclusion herein, and each parties' directors and officers have relied on the other party for any information concerning such party.

Forward-Looking Information

This news release contains forward-looking information based on current expectations. Statements about, among other things, the closing of the Transaction and the future business plans and prospects of CTI are forward looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such factors include, but are not limited to: the parties' ability to satisfy various closing conditions of the Transaction, including receipt of all regulatory and shareholder approvals and the ability of CTI to execute on its current business plan. Although such statements are based on management's reasonable assumptions at the date such statements are made, there can be no assurance that the Transaction will occur or that, or if the Transaction does occur, it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. Astar and FinCanna assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.